Zai Lab Announces Upcoming Presentations at December Investor Conferences
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced its participation in two upcoming virtual investor conferences in December 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced its participation in two upcoming virtual investor conferences in December 2021. The events include a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 1 at 8:25 a.m. ET, and another at the SVB Leerink CybeRx Series on December 8 at 9:00 a.m. ET. Interested investors can access the webcast links through the 'Events & Presentations' section on Zai Lab's website. The company focuses on innovative therapies in oncology, autoimmune disorders, infectious diseases, and neuroscience.
Details
News Market Reaction – ZLAB
The recorded move for ZLAB in the trading session of this news was -2.38%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following virtual investor conferences in December:
The 4th Annual Evercore ISI HealthCONx Conference
Fireside Chat: Wednesday, December 1, 2021, 8:25 a.m. ET
SVB Leerink CybeRx Series: Global Biopharma Spotlight
Fireside Chat: Wednesday, December 8, 2021, 9:00 a.m. ET
Webcast link of the 4th Evercore ISI HealthCONx Conference will be available under “Events & Presentations” in the “Investor Relations” section of Zai Lab’s website. An archived replay will be available for 90 days following the event.
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.
For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.
For more information, please contact:
ZAI LAB CONTACTS:
Investor Relations: Ron Aldridge / Lina Zhang
+1 (781) 434-8465 / +86 136 8257 6943
ronald.aldridge@zailaboratory.com / lina.zhang@zailaboratory.com
Media: Danielle Halstrom / Xiaoyu Chen
+1 (215) 280-3898 / +86 185 0015 5011
danielle.halstrom@zailaboratory.com / xiaoyu.chen@zailaboratory.com
Zai Lab Limited
Source: Zai Lab Limited
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.